Previous Close | 92.98 |
Open | 91.90 |
Bid | 95.90 x 800 |
Ask | 99.97 x 2200 |
Day's Range | 91.65 - 96.50 |
52 Week Range | 70.73 - 96.50 |
Volume | |
Avg. Volume | 1,190,782 |
Market Cap | 17.772B |
Beta (5Y Monthly) | 0.33 |
PE Ratio (TTM) | 330.41 |
EPS (TTM) | 0.29 |
Earnings Date | Oct 25, 2022 - Oct 31, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 111.95 |
Subscribe to Yahoo Finance Plus to view Fair Value for BMRN
BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Q2 sales reached $533.8 million, up 6% Y/Y, beating the consensus of $521.47 million. BioMarin said the increase was achieved "despite continued erosion of the U.S. Kuvan market." Total revenues grew 13% Y/Y, excluding Kuvan. The company reported EPS of $0.15 compared to $0.07 a year ago, beating the consensus of $0.11. Voxzogo for achondroplasia (dwarfism) reported sales of $34.4 million. An estimated 446 children were being treated with commercial V
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?